Glaukos Corporation (GKOS) Stock

Healthcare · Medical Devices · Member of Other US Stocks

Glaukos Corporation (GKOS) closed at USD 167.89 on 2026-10-14, a change of +115.8 % over the past year, with a market capitalization of USD 9.77B.

Glaukos Corporation recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Glaukos Corporation key figures

Previous close

USD 167.89 (2026-10-14)

1-year change

+115.8 %

Market cap

USD 9.77B

Enterprise value

USD 9.58B

P/E ratio (trailing)

-50.03

P/E ratio (forward)

315.83

EPS (trailing)

-3.31

EPS (forward)

0.52

PEG ratio

n/a

Price to book

14.28

Revenue growth

49.5 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

4.67

Employees

1,094

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Glaukos Corporation

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal delivery of pharmaceutically active compounds for the treatment of anterior segment eye disorders; and retinal XR platform to treat age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment retinal diseases. It sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors. The company was formerly known as Transdx, Inc. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Glaukos Corporation and compare it with other stocks.